Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
| Autor: | Stanley R. Hamilton, Bruce D. Minsky, Jennifer Clark, Christopher H. Lieu, Carmen J. Allegra, Scott Kopetz, Robyn Temple-Smolkin, Veena M. Singh, Christina B. Ventura, Carol Colasacco, Daniel J. Sargent, Allison M. Cushman-Vokoun, R. Bryan Rumble, Joseph Willis, Antonia R. Sepulveda, Jan A. Nowak, Federico A. Monzon, Noralane M. Lindor, William K. Funkhouser, Wayne W. Grody |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Pathology Colorectal cancer DNA Mutational Analysis Alternative medicine MEDLINE Article Genomic Instability Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Gene Frequency Mutation Rate Biomarkers Tumor medicine Humans Genetic Testing Molecular Targeted Therapy Pathology Molecular American Medical Association Genetic testing Evidence-Based Medicine Pathology Clinical Clinical pathology medicine.diagnostic_test Molecular pathology business.industry Disease Management General Medicine Evidence-based medicine Guideline Prognosis medicine.disease United States ErbB Receptors Medical Laboratory Technology Treatment Outcome 030104 developmental biology Molecular Diagnostic Techniques 030220 oncology & carcinogenesis Family medicine Mutation Practice Guidelines as Topic Colorectal Neoplasms business Signal Transduction |
| DOI: | 10.17615/vf3q-g225 |
| Popis: | Objectives.— To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods.— The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results.— Twenty-one guideline statements were established. Conclusions.— Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|